Provided by Tiger Trade Technology Pte. Ltd.

Alzamend Neuro, Inc

0.7758
-0.2442-23.94%
Post-market: 0.79000.0142+1.83%19:30 EST
Volume:93.31K
Turnover:82.84K
Market Cap:3.72M
PE:-0.33
High:1.00
Open:1.00
Low:0.7536
Close:1.02
52wk High:2.54
52wk Low:0.7536
Shares:4.79M
Float Shares:4.78M
Volume Ratio:2.51
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3210
EPS(LYR):-2.6287
ROE:-163.23%
ROA:-76.44%
PB:0.64
PE(LYR):-0.30

Loading ...

Alzamend Neuro Reports Preliminary AL001 Brain Connectivity Imaging Findings

TIPRANKS
·
Nov 19

Alzamend Neuro Says Massachusetts General Ends AL001 Bipolar Disorder Trial Agreement

Reuters
·
Nov 18

Alzamend Neuro Cuts Preferred Stock Financing to $10 Million from $25 Million in Amended Agreement

Reuters
·
Nov 11

Alzamend Neuro Highlights Early AL001 Brain Lithium Data

TIPRANKS
·
Sep 29

Alzamend Neuro Regains NASDAQ Listing Compliance After Meeting Stockholders’ Equity Rule

Reuters
·
Sep 16

Alzamend Neuro Regains Compliance with NASDAQ Listing Standards

THOMSON REUTERS
·
Sep 16

Alzamend Neuro Inc Reports Results for the Quarter Ended April 30 - Earnings Summary

Reuters
·
Sep 15

Alzamend Neuro Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview

Reuters
·
Sep 12

Alzamend Neuro Q1 EPS $(0.68) Misses $(0.56) Estimate, Sales $0.00, Same YoY

Benzinga Earnings
·
Sep 11

Alzamend Neuro Q1 FY27 Net Loss Narrows 12% to $3.03 Million

Reuters
·
Sep 11

Alzamend Neuro Inc Expected to Post a Loss of 56 Cents a Share - Earnings Preview

Reuters
·
Sep 05

Alzamend Neuro Director Milton C. Ault III Sells 2,000 Shares Worth $3,116.20

Reuters
·
Aug 31

Alzamend Neuro Announces Annual Shareholder Meeting

Reuters
·
Aug 29

Alzamend Neuro - Files to Register Resale of up to 98.4 Mln Common Shares by Selling Stockholder - SEC Filing

THOMSON REUTERS
·
Aug 22

Alzamend Neuro registers to sell 98.39M shares of common stock for holders

TIPRANKS
·
Aug 22

Alzamend Neuro Phase 1/2A AL001 Lithium fMRI Data Wins Poster Slot at SfN Neuroscience 2026

Reuters
·
Aug 20

Alzamend Neuro Price Target Raised to $26.00/Share from $25.00 by Ascendiant Capital

Dow Jones
·
Aug 19

Alzamend Neuro Phase 1/2A AL001 Lithium Imaging Data Wins Oral Slot at ISMRM X-Nuclei MR Workshop

Reuters
·
Aug 18

Alzamend Neuro Initial Beneficial Ownership Filing Names Hyperscale Data as Director by Deputization

Reuters
·
Aug 05

Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

THOMSON REUTERS
·
Aug 04